Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37980893)
Watch
English
Management of treatment failure in chronic hepatitis B.
scientific article published on January 2012
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
title
Management of treatment failure in chronic hepatitis B
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
main subject
chronic hepatitis
1 reference
based on heuristic
inferred from title
author
Fabien Zoulim
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
author name string
Stephen Locarnini
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
publication date
1 January 2012
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
published in
Journal of Hepatology
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
volume
56 Suppl 1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
page(s)
S112-22
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
cites work
Molecular virology and the development of resistant mutants: implications for therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus immunopathogenesis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
EASL Clinical Practice Guidelines: management of chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir for the treatment of chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Histological outcome during long-term lamivudine therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lamivudine for patients with chronic hepatitis B and advanced liver disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Telbivudine versus lamivudine in patients with chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus resistance to nucleos(t)ide analogues.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cellular and virological mechanisms of HBV drug resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HBV drug resistance: mechanisms, detection and interpretation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Variant of hepatitis B virus with primary resistance to adefovir
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B virus with primary resistance to adefovir.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evolution of multi-drug resistant hepatitis B virus during sequential therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HIV Drug Resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis B: reflections on the current approach to antiviral therapy.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro models for studying hepatitis B virus drug resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro characterization of viral fitness of therapy-resistant hepatitis B variants
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Small animal model systems for studying hepatitis B virus replication and pathogenesis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
[Treatment of chronic hepatitis B: adherence and safety]
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HIV-1 viral load blips are of limited clinical significance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960012-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0168-8278(12)60012-9
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
PubMed publication ID
22300461
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22300461
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22300461%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
